Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gemcitabine in bladder cancer.

C N Sternberg1

  • 1Department of Medical Oncology, San Raffaele Scientific Institute, Rome, Italy.

Seminars in Oncology
|March 4, 2000
PubMed
Summary
This summary is machine-generated.

Gemcitabine-based chemotherapy offers a promising new approach for advanced transitional cell carcinoma, improving response rates and tolerability. Further research is needed to confirm its efficacy and overcome treatment resistance in bladder cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy.

Urologic oncology·2025
Same author

Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.

ESMO open·2023
Same author

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.

ESMO open·2022
Same author

Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.

ESMO open·2021
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Urothelial Carcinomas
  • Medical Chemotherapy

Background:

  • Systemic chemotherapy is crucial for long-term survival in advanced urothelial carcinoma.
  • Methotrexate/vinblastine/doxorubicin/cisplatin (MVAC) is the current standard, yielding up to 72% response rates.
  • Understanding treatment resistance mechanisms is vital for effective management.

Purpose of the Study:

  • To evaluate the role of gemcitabine in treating advanced transitional cell carcinoma.
  • To assess gemcitabine's efficacy as a single agent and in combination therapies.
  • To explore strategies for overcoming chemotherapy resistance.

Main Methods:

  • Review of current systemic chemotherapy regimens for advanced urothelial carcinoma.
  • Analysis of gemcitabine's response rates and toxicity profile as a single agent.

Related Experiment Videos

  • Evaluation of gemcitabine combination therapies, including with cisplatin, taxanes, and carboplatin.

    • Main Results:

    • Gemcitabine monotherapy shows 23-28% response rates with good tolerability.
    • Gemcitabine plus cisplatin achieves 66% response rates while maintaining tolerability.
    • Preliminary data on other gemcitabine combinations are promising but require Phase III confirmation.

    Conclusions:

    • Gemcitabine represents a significant advancement in bladder cancer chemotherapy.
    • Gemcitabine-based regimens offer improved outcomes and tolerability compared to older standards.
    • Further investigation into resistance mechanisms and novel drug delivery is warranted.